Ajooni Biotech Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech has confirmed to NSE that there is no deviation or variation in the use of funds raised through its Rights Issue (allotted on June 6, 2024) for the quarter ended June 30, 2025. The company had raised approximately Rs. 42.31 crore via the Rights Issue. As of June 30, 2025, total utilization stood at about Rs. 33.50 crore, leaving roughly Rs. 8.81 crore yet to be deployed. Working capital was the only object fully utilized (Rs. 15.45 crore), while Plant & Machinery (Rs. 5.22 crore of Rs. 8.45 crore) and general corporate purposes (Rs. 5.12 crore of Rs. 10.14 crore) remain partially used. The statement was reviewed by the Audit Committee and approved by the Board on August 11, 2025.
Positive for shareholders — the company is using Rights Issue funds in line with disclosed objects with no diversion, reinforcing governance discipline. However, the slower-than-complete deployment of capital (especially for Plant & Machinery and general corporate purposes) may delay the intended operational benefits and could draw investor attention to deployment timelines.